Risk Factors for Nonadherence to Antihypertensive Treatment

Hypertension

Volumn 69, Issue 6, 2017, Pages 1113-1120

  Gupta, Pankaj ^a,b,c   Patel, Prashanth ^a,b,c   Štrauch, Branislav ^e   Lai, Florence Y ^b,c   Akbarov, Artur ^g   Marešová, Věra ^e   White, Christobelle M J ^c   Petrák, Ondřej ^e   Gulsin, Gaurav S ^a,b,c   Patel, Veena ^h   Rosa, Ján ^e,f   Cole, Richard ^a   Zelinka, Tomáš ^e   Holaj, Robert ^e   Kinnell, Angela ^a   Smith, Paul R ^a   Thompson, John R ^d   Squire, Iain ^b,c   Widimský, Jiří ^e   Samani, Nilesh J ^b,c   Williams, Bryan ^i,j   Tomaszewski, MacIej ^g,k   more..

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e Third Department of Medicine   (United States)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h DERBY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j and University of Bristol   (United Kingdom)

^k MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

adherence; blood pressure; diuretics; hypertension; polypharmacy

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN INHIBITOR;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD ANALYSIS; CZECH REPUBLIC; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SEX; TREATMENT REFUSAL; UNITED KINGDOM; URINALYSIS; AGED; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COHORT ANALYSIS; MEDICATION COMPLIANCE; MULTICENTER STUDY; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; COHORT STUDIES; CZECH REPUBLIC; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UNITED KINGDOM;

EID: 85019880651     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08729     Document Type: Article

References (40)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223. doi: 10.1016/S0140-6736(05)17741-1.
2. Kotseva K, Wood D, De Bacquer D, et al; EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-648. doi: 10.1177/2047487315569401.
3. Yoon S, Fryar C, Carroll M. Hypertension Prevalence and Control Among Adults: United States, 2011-2014. NCHS Data Brief, No 220. Hyattsville, MD: National Center for Health Statistics. www.cdc.gov/nchs/data/databriefs/ db220.htm. Updated 2015. Accessed December 18, 2016.
4. NICE. NICE clinical guideline 76: medicines adherence. www.nice.org. uk/CG76. Updated 2009. Accessed April 5, 2016.
5. IMS Institute of Healthcare Informatics. Avoidable costs in US health care. www.imshealth.com/en-ZA/thought-leadership/ims-institute/ reports/avoidable-costs. Updated 2013. Accessed October 23, 2016.
6. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774. doi: 10.1097/ HJH.0b013e32835e2286.
7. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861. doi: 10.1136/heartjnl-2013-305063.
8. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011. doi: 10.1002/14651858.CD000011.pub4.
9. Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35:3267-3276. doi: 10.1093/ eurheartj/ehu364.
10. Mennini FS, Marcellusi A, von der Schulenburg JM, Gray A, Levy P, Sciattella P, Soro M, Staffiero G, Zeidler J, Maggioni A, Schmieder RE. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16:65-72. doi: 10.1007/ s10198-013-0554-4.
11. Rosa J, Widimský P, Touŝek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65:407-413. doi: 10.1161/ HYPERTENSIONAHA.114.04019.
12. Patel P, Gupta PK, White CM, Stanley AG, Williams B, Tomaszewski M. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30:368-373. doi: 10.1038/jhh.2015.103.
13. Hameed MA, Tebbit L, Jacques N, Thomas M, Dasgupta I. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30:83-89. doi: 10.1038/jhh.2015.38.
14. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;2:CD004804.
15. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi: 10.1155/2015/217047.
16. Pandey A, Raza F, Velasco A, Brinker S, Ayers C, Das SR, Morisky DE, Halm EA, Vongpatanasin W. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatmentresistant hypertension. J Am Soc Hypertens. 2015;9:420-426.e2. doi: 10.1016/j.jash.2015.04.004.
17. Gonzalez O, Iriarte G, Rico E, Ferreirós N, Maguregui MI, Alonso RM, Jiménez RM. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2685-2692. doi: 10.1016/j. jchromb.2010.07.026.
18. Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, Chytil L, Mareŝová V, Kurcová I, Holaj R, Wichterle D, Widimský J Jr. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455-2461. doi: 10.1097/ HJH.0b013e3283652c61.
19. Florczak E, Tokarczyk B, Warcho?-Celi?ska E, Szwench-Pietrasz E, Prejbisz A, Gosk M, Kabat M, Narkiewicz K, Januszewicz A, Ka?a M. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125:65-72.
20. Bokhour BG, Berlowitz DR, Long JA, Kressin NR. How do providers assess antihypertensive medication adherence in medical encounters? J Gen Intern Med. 2006;21:577-583. doi: 10.1111/j.1525-1497.2006. 00397.x.
21. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-1288. doi: 10.1345/aph.1H018.
22. World Health Organisation. Adherence to long-term therapies: evidence for action. www.who.int/chp/knowledge/publications/adherence-full- report.pdf. Updated 2003. Accessed October 12, 2016.
23. Iriarte G, Gonzalez O, Ferreirós N, Maguregui MI, Alonso RM, Jiménez RM. Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:3045-3053. doi: 10.1016/j.jchromb.2009.07.018.
24. Chytil L, Cva?ka J, Mareŝová V, Ŝtrauch B, Widimský J Jr, Ŝtícha M, Slana? O. Development of a fast LC-MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS. J Mass Spectrom. 2010;45:1179-1185. doi: 10.1002/jms.1809.
25. Chytil L, Strauch B, Cva?ka J, Mareŝová V, Widimský J Jr, Holaj R, Slana? O. Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:3167-3173. doi: 10.1016/j.jchromb.2010.09.032.
26. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. www.R-project.org. Updated 2015. Accessed May 10, 2016.
27. Carey V. Ported to R by Lumley T, Ripley B. Generalized estimation equation solver. R package version 4.13-19. https://CRAN.R-project.org/ package=gee. Updated 2015. Accessed June 10, 2016.
28. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407. doi: 10.1161/ HYPERTENSIONAHA.109.139816.
29. Morrison VL, Holmes EA, Parveen S, Plumpton CO, Clyne W, De Geest S, Dobbels F, Vrijens B, Kardas P, Hughes DA. Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. Value Health. 2015;18:206-216. doi: 10.1016/j.jval.2014.12.013.
30. Grigoryan L, Pavlik VN, Hyman DJ. Predictors of antihypertensive medication adherence in two urban health-care systems. Am J Hypertens. 2012;25:735-738. doi: 10.1038/ajh.2012.30.
31. Watanabe JH, Bounthavong M, Chen T, Ney JP. Association of polypharmacy and statin new-user adherence in a Veterans Health Administration population: a retrospective cohort study. Ann Pharmacother. 2013;47:1253-1259. doi: 10.1177/1060028013502000.
32. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Metaanalysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-1621. doi: 10.1161/CIRCULATIONAHA.110.983874.
33. Swain S, Hariharan M, Rana S, Chivukula U, Thomas M. Doctor-patient communication: impact on adherence and prognosis among patients with primary hypertension. Psychol Stud. 2015;60:25-32.
34. Degli Esposti L, Saragoni S, Benemei S, Batacchi P, Geppetti P, Di Bari M, Marchionni N, Sturani A, Buda S, Degli Esposti E. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011;3:47-54. doi: 10.2147/CEOR.S15619.
35. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens. 2004;18:607-613. doi: 10.1038/sj.jhh.1001721.
36. Maguire LK, Hughes CM, McElnay JC. Exploring the impact of depressive symptoms and medication beliefs on medication adherence in hypertension-a primary care study. Patient Educ Couns. 2008;73:371-376. doi: 10.1016/j.pec.2008.06.016.
37. Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, Lohr KN. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175:76-87. doi: 10.1001/jamainternmed.2014.5841.
38. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388:2665-2712. doi: 10.1016/S0140-6736(16)31134-5.
39. Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32:507-510. doi: 10.1136/jme.2005.012138.
40. Moffat A, Osselton D, Widdop B, Watts J. Clarke's Analysis of Drugs and Poisons. 4th ed. London, UK: Pharmaceutical Press; 2011.